SUNRISE, Fla., June 2 /PRNewswire/ -- Bioheart Inc. and PharmaCell announced today the grand opening of a GMP lab facility in Maastricht, The Netherlands. The lab facility is in compliance with EU Good Manufacturing Practices (EU-GMP). This new lab is an advanced research facility that also has GMP cell production capabilities to support research related to Bioheart’s adult muscle stem cell technology. Bioheart has developed MyoCell(TM), a cell therapy that involves extracting and culturing cells from a patient’s own thigh muscle. These cells are inserted back into the patient’s damaged heart region via the MyoCath(R), a minimally-invasive injection-catheter system. The research at the lab could lead to new intellectual property development and more job creation for the Maastricht region.
“We are excited about the opening of this GMP facility that will support our research,” said Howard J. Leonhardt, Chairman and CEO of Bioheart. “We chose the Maastricht region due to its highly educated workforce and its ideal location with close proximity to top research institutes such as the University of Maastricht,” he added.
About PharmaCell:
PharmaCell is a unique enterprise which grows cells and conducts research for third parties. PharmaCell’s facility contains three small cell cultivation units and a GMP production unit in the Biopartner Center in Maastricht. PharmaCell meets the needs of companies for product development, clinical testing or for the initial stages of commercialization.
About Bioheart:
Bioheart, Inc. is focused on developing and commercializing cell-based therapies for the treatment of cardiovascular diseases, including myocardial infarction and heart failure. The Company is currently enrolling patients in its European Phase II clinical trial named SEISMIC to test its lead product candidates, MyoCell(TM) and MyoCath(R). The MyoCell(TM) implantation therapy is designed to regenerate areas of damaged myocardial tissue. MyoCath(R) is a percutaneous needle injection catheter engineered to deliver cell therapy or other compounds to myocardial tissue. For more information about Bioheart, please visit http://www.bioheartinc.com or telephone Mr. Jason Griffeth at 954-835-1500.
Statements in this press release that are not strictly historical may be “forward-looking” statements, which involve risks and uncertainties. There can be no assurance that Bioheart, Inc. will be able to commercially develop cardiovascular cell therapy products, that necessary regulatory approvals will be obtained or that any clinical trials will be successful or that the proposed treatments will prove to be safe and/or effective.
Bioheart Inc.
CONTACT: Jason Griffeth for Bioheart Inc., +1-954-835-1500
Web site: http://www.bioheartinc.com/
